Kisspeptin: discovery and desensitisation

The melanoma origin

The starting point was a metastasis-suppressor gene identified in human melanoma research in 1996. Introducing KISS1 into metastatic melanoma cells suppressed metastasis in nude mice without abolishing tumour formation. That is a cell-line and mouse-model finding, with a very different question from the one a menopause site brings to it.

I enjoy this awkward origin. A molecule can arrive in a conversation carrying a tidy label while its history runs through quite unrelated experiments. The melanoma work gives kisspeptin a beginning that resists a simple reproductive slogan.

Puberty and GPR54

In human genetics and a mouse knockout model reported in 2003, loss of GPR54 function caused failure of reproductive maturation. The human finding involved idiopathic hypogonadotropic hypogonadism with absent or incomplete puberty. GPR54 is also called KISS1R, the kisspeptin receptor.

This is the reproductive connection that impresses me: a naturally occurring loss of receptor function, together with a mouse model reproducing the phenotype. It gives the signalling system considerable biological significance. It also describes the consequences of losing a function, which leaves a separate question about the consequences of adding a peptide.

The fading LH response

In women with hypothalamic amenorrhea, repeated kisspeptin-54 exposure produced a diminishing response. The acute mean LH increment was 24.0 +/- 3.5 IU/L within 4 h on day 1; by day 14, the response was 2.5 +/- 2.2 IU/L. The study calls the loss of responsiveness tachyphylaxis.

That finding spoils the simple appeal of a switch. I think it makes the biology better: a signal has a history, and the system responds differently after repeated exposure. A review of KISS1R pharmacology describes desensitisation, internalisation and receptor recycling as parts of the balance between sustained and attenuated signalling.

LH pulses in hypothalamic amenorrhea

Another infusion experiment in women with hypothalamic amenorrhea restored pulsatile LH secretion, although the highest infusion rate produced tachyphylaxis during the experiment. The condition studied was hypothalamic amenorrhea. A menopause outcome would require evidence from a menopause population.

Taken together, these experiments make the timing and persistence of a response interesting scientific questions. A universal expectation of more signalling strikes me as poorly suited to a system whose response has already faded. The useful work is in explaining that behaviour, including which parts of it recur in other populations.

Brief human exposure

A randomized crossover study reported in 2025 increased LH without significantly changing state anxiety, cortisol, blood pressure or heart rate compared with placebo. Those observations describe the monitored exposure.

The systematic review published in 2025 identified 29 interventional clinical trials from databases searched through February 2023 and described kisspeptin as pre-approval. That is the review's account of the clinical landscape, with its search period intact.

My interest survives these limits. The fading response, the hormone pulses and the unchanged anxiety result each give the subject more substance than an all-purpose rejuvenation claim. Bone turnover offers another focused experiment in which the measured result is worth examining closely.